KIRYAT ONO, Israel & ATLANTA--(BUSINESS WIRE)--Aug. 22, 2006--GammaCan International (OTCBB: GCAN), and Life Therapeutics (ASX: LFE) today announced the signing of a Term Sheet for a collaboration to jointly develop VitiGam, an innovative anti-cancer product designed to target metastatic malignant melanoma patients with Stage III and IV disease. Advanced stage melanoma represents a large unmet medical need - there are no safe and effective therapies available to patients today.
